Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 11/20 | 0.73 |
| ▸ | ESR1 | P03372 | 10/20 | 0.73 |
| ▸ | APP | P05067 | 3/20 | 0.58 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6171301 | 0.91 | ESR2 (0.68) | ESR2ESR1APPSULT1A1NPC1 | |
| SCHEMBL1665299 | 0.87 | NPC1 (0.56) | ESR2ESR1APPNPC1TP53 | |
| SCHEMBL31310542 | 0.87 | NPC1 (0.56) | ESR2ESR1APPNPC1TP53 | |
| SCHEMBL7645052 | 0.85 | ESR1 (0.69) | ESR2ESR1APPSULT1A1HDAC6 | |
| Raloxifene Core SCHEMBL2567321 | 0.85 | ESR1 (1.00) | ESR2ESR1APP | |
| Raloxifene Core SCHEMBL29941293 | 0.85 | ESR1 (1.00) | ESR2ESR1APP | |
| SCHEMBL5681634 | 0.83 | ESR1 (0.58) | ESR2ESR1APPNPC1TP53 | |
| SCHEMBL7642766 | 0.82 | ESR1 (0.65) | ESR2ESR1APPHSD17B10HDAC6 | |
| SCHEMBL3139631 | 0.82 | ESR1 (1.00) | ESR2ESR1APPHDAC6 | |
| SCHEMBL7450918 | 0.81 | ESR1 (0.63) | ESR2ESR1APPSULT1A1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6395769-B1 | ACTIVATION ESTROGEN; THERAPY FOR OSTEOPOROSIS, ANTILIPEMIC AGENTS | ELI LILLY AND COMPANY | 2002-05-28 | — | — | US | claimed |
| US-6096781-A | 2-PHENYL-1-BENZOTHIOPHENE DERIVATIVES ARE USEFUL FOR TREATMENT OF OSTEOPOROSIS AND HYPERLIPEMIA | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | claimed |
| EP-0920862-A1 | 2-Arylbenzo b thiophenes useful for the treatment of estrogen deprivation syndrome | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | claimed |
| US-8124776-B2 | Process and intermediates for preparing arzoxifene | ELI LILLY AND COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124776-B2 | Process and intermediates for preparing arzoxifene | ELI LILLY AND COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124776-B2 | Process and intermediates for preparing arzoxifene | ELI LILLY AND COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100137602-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ARZOXIFENE | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| US-20100137602-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ARZOXIFENE | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| US-20100137602-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ARZOXIFENE | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| WO-2008115686-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ARZOXIFENE | ELI LILLY AND COMPANY (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115686-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ARZOXIFENE | ELI LILLY AND COMPANY (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2007140183-A1 | FXR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-6921827-B2 | Process for preparing 3-aryl-benzo{b} thiophenes | ELI LILLY AND COMPANY (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040132775-A1 | Process for preparing 3-aryl-benzo{b} thiophenes | LUKE WAYNE DOUGLAS (US) | 2004-07-08 | — | — | US | disclosed |
| US-6395769-B1 | ACTIVATION ESTROGEN; THERAPY FOR OSTEOPOROSIS, ANTILIPEMIC AGENTS | ELI LILLY AND COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-6096781-A | 2-PHENYL-1-BENZOTHIOPHENE DERIVATIVES ARE USEFUL FOR TREATMENT OF OSTEOPOROSIS AND HYPERLIPEMIA | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0920862-A1 | 2-Arylbenzo b thiophenes useful for the treatment of estrogen deprivation syndrome | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132775-A1 | Process for preparing 3-aryl-benzo{b} thiophenes | TBCB, CYP1B1, TST | ESR2 3551/4885ESR1 4134/4885APP 1569/4885 |
| US-20100137602-A1 | PROCESS AND INTERMEDIATES FOR PREPARING ARZOXIFENE | CYP2F1, CYP4X1, CYP3A43 | ESR2 699/4885ESR1 829/4885APP 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.